Eos Energy stock falls after Fuzzy Panda issues short report
Investing.com - Citizens has reiterated its Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ:KURA), citing the company’s progress toward potential regulatory approval for its menin inhibitor ziftomenib. According to InvestingPro data, analysts maintain a strong bullish consensus on KURA, with price targets ranging from $11 to $40, suggesting significant upside potential.
The research firm highlighted that competitor Syndax’s menin inhibitor revumenib received approval on Friday for relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) patients, but with an updated black box warning that now includes QTc prolongation and Tosades de Pointes alongside the previously noted differentiation syndrome.
Citizens suggested these additional warnings for the competing drug could potentially differentiate Kura’s ziftomenib in community settings and in chemotherapy combinations, though it expects differentiation syndrome warnings to appear across the menin inhibitor class.
Kura’s ziftomenib has a PDUFA date of November 30, 2025, with Phase 1b KOMET-007 data expected at the ASH 2025 conference.
The firm pointed to Kura’s pro forma cash position of $730.7 million and its early FTI program results as additional factors supporting its view that the shares remain undervalued ahead of the potential approval in relapsed/refractory NPM1-mutated AML. InvestingPro analysis confirms this assessment, with the stock currently trading below its Fair Value. Discover more insights and 10+ additional ProTips for KURA, along with comprehensive research reports covering 1,400+ US stocks, exclusively on InvestingPro.
In other recent news, Kura Oncology has received a $30 million milestone payment from Kyowa Kirin. This payment was triggered by the dosing of the first patient in the KOMET-017 Phase 3 trials of ziftomenib, an investigational oral menin inhibitor for acute myeloid leukemia. The trials are global, randomized, double-blind, and placebo-controlled, evaluating the drug in combination with chemotherapy regimens. Additionally, Kura Oncology presented promising data for its farnesyl transferase inhibitor programs at the European Society for Medical Oncology Congress. The preliminary data showed that the drug darlifarnib demonstrated potential as a combination therapy, particularly in renal cell carcinoma patients. In related developments, H.C. Wainwright has reiterated a Buy rating with a $40 price target for Kura Oncology. The firm highlighted the positive results from Phase 1 trials evaluating Kura’s FTI candidates, darlifarnib and tipifarnib, in treating multiple solid tumors. These developments reflect significant progress in Kura’s ongoing research and collaborations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.